Neuro-Behçets in a Child

Zachary A. Vesoulis, MD¹, Rafael Galindo, MD, PhD², Bradley W. Ornstein, MD¹, and Andrew J. White, MD¹

Abstract
We describe a case of neuro-Behçet disease diagnosed in a 12-year-old girl. This patient presented with recurrent oral ulcers, incontinence, spastic gait, blurry vision, and asymmetrical lower extremity hypertonia. Extensive testing revealed punctate lesions through the central nervous system, vitritis, papillitis, and uveitis. A thorough infectious and neoplastic workup was negative. She was treated with pulse steroids and azathioprine with gradual improvement in her gait and ophthalmologic findings. Although rare, primary neuro-Behçet should be considered in pediatric patients with neurologic abnormalities and recurrent aphthous ulcers without other explanation.

Keywords
MRI, uveitis, vitritis, papillitis, hypertonia, incontinence, urinary tract infection, azathioprine

Written by Hippocrates of Kos in the fifth century BC, the third volume of Epidemion contains a description of a series of patients with relapsing fever, oral and genital ulcers, and "fungal" growths in the eye and eyelids that frequently led to blindness. In 1930, over 2000 years after that first description, another Greek physician, Benediktos Adamantiades, presented a lecture titled "A case of relapsing iritis with hypopyon" in which he described a male patient with oral and genital ulcers, iritis, and arthritis.¹ In 1937, Hulusi Behçet, a dermatologist from Istanbul described the so-called "triple-symptom complex" with symptoms similar to those described by Adamantiades.²

Since that time, cases of Behçet disease have been found along the path of the Silk Road, a 4000-mile long ancient trading route which spanned from the Mediterranean Ocean to China.³ Prevalence varies in countries along the path, ranging from 2 to 370 per 100 000 with the highest prevalence noted in Turkey and Japan. Prevalence in the non-Silk Road countries such as the United States is substantially lower at 0.33 per 100 000⁴ and even more rare in children, which encompass only 2% to 3% of all cases of Behçet disease.⁴ Additional epidemiologic data have shown an increased relative risk for those with either human lymphocyte antigens (HLA) B5 or B51, with HLA B51 carrying a relative risk for Behçet disease of 6.3.⁵

In this report, we describe an unusual presentation of primary neuro-Behçet disease in a 12-year-old girl.

Case Report
Approximately 2 years prior to her initial neurological evaluation, a 12-year-old girl developed both urinary tract infections in the context of recurrent stress-induced and nocturnal urinary incontinence. One year prior to her presentation, she began to develop recurrent oral ulcers, at the time thought to be "cold sores." Eight months prior to her presentation, she began to experience intermittent back pain and blurred vision, sporadic abdominal pain, and progressive clumsiness in her lower extremities that caused frequent falls. Two weeks prior to her initial visit at our institution, she was admitted to a psychiatric unit after a suicide attempt.

Due to her progressive symptoms, she was referred to our pediatric neurology clinic for evaluation. At her initial visit, her examination was notable for asymmetric spasticity (right greater than left) in her lower extremities with prolonged ankle...
Within 3 days of therapy initiation, an improvement in both her gait and vision occurred. She transitioned to 1 mg/kg of prednisone and was discharged home. One month after steroid initiation, a repeat MRI demonstrated that the punctuate lesions previously seen throughout the brain and spinal cord were no longer contrast enhancing. Four months after the start of steroid treatment, the vitritis and papillitis had resolved, she was able to walk a longer distance with less effort and fatigue, and her incontinence had improved substantially. The prednisone was gradually tapered and stopped.

Unfortunately, 2 months after cessation of steroids her gait abnormalities, visual disturbances, arthralgias, and urinary incontinence abruptly worsened, prompting a repeat MRI scan that revealed progression of her contrast-enhancing spinal and brain lesions as compared to the initial study. Given the severity of her symptoms, brain, bone marrow, and conjunctival biopsies were performed. The conjunctival biopsy did not reveal any abnormalities. Three separate central nervous system biopsy specimens were obtained from the dura, parenchyma, and ependymal lining. Both the dural and parenchymal specimens were unremarkable. The ependymal biopsy demonstrated atypical areas of well-demarcated inflammation (reactive astrocytes, lymphocytes, macrophages, and activated microglia) and proportional loss of axons and myelin in a perivascular distribution but without clear evidence of vasculitis as shown in Figure 3.

Given the evidence of neuroinflammation on biopsy, an empiric course of intravenous immunoglobulin was initiated. Despite treatment, her visual complaints and gait disturbance continued to worsen. Plasma exchange was then performed a total of 7 times with incremental improvement in her symptoms after each treatment. Given the constellation of her symptoms (visual and gait disturbances, arthralgia, and psychiatric problems), ophthalmologic (vitritis, papillitis, and uveitis) and biopsy findings (proportional loss of myelin and axons in an inflammatory background), and history of recurrent oral ulcers, a presumptive diagnosis of neuro-Behçet disease was made. Azathioprine was initiated at 50 mg/d and was well tolerated. Twenty-four months after starting azathioprine, she regained her original lower extremity strength and visual acuity, has no complaints of abdominal pain, and has not had any further gait disturbance.

**Discussion**

The cause of Behçet disease remains elusive, although many theories have been proposed. Behçet proposed that the Herpes virus was the cause of the disease and indeed there is evidence showing a greater presence of herpes simplex virus DNA in saliva in patients with Behçet disease, although nearly 60% of patients with Behçet disease had no herpes simplex virus isolated.

An autoimmune model for the disease has also been proposed after the observation of CD4+ T cells present in perivascular infiltrates and increased circulating levels of interleukin 8. The autoimmune proposal was bolstered after gene

---

**Figure 1.** T1 brain and spine images with contrast. On left, axial slice at the level of the brain stem and cerebellum and on the right, sagittal view of spine. Arrows highlight contrast-enhanced lesions seen throughout the spinal axis.
Table 1. Summary of Diagnostic Workup.

| Inflammatory                          | Positive (1:320, speckled) |
|--------------------------------------|----------------------------|
| ANA                                   | 0 units/L                  |
| Angiotensin-converting enzyme (serum)| 7 units/L                  |
| Angiotensin-converting enzyme         | Normal                     |
| (cerebrospinal fluid)                |                            |
| Antineutrophil cytoplasmic antibodies| Normal                     |
| Erythrocyte sedimentation rate        | Normal                     |
| C-reactive protein                    | Normal                     |
| SS-A and SS-B                         | Normal                     |
| C3                                    | Normal                     |
| C4                                    | Normal                     |
| Oligoclonal bands (serum)            | 1 band                     |
| Oligoclonal bands (cerebrospinal fluid) | 3 bands                   |
| Neuromyelitis optica antibody         | Negative × 3               |
| (cerebrospinal fluid)                |                            |

| Infectious                           | >100,000 colony-forming unit of *Escherichia coli* |
| Urine culture                        | Glucose 58 mg/dL                      |
| Cerebrospinal fluid analysis         | Protein level 65 mg/dL               |
| Cerebrospinal fluid culture          | Relative lymphocytosis (20 nucleated cells/high-power field, 97% lymphocytes) |
| Blood culture                        | No growth                             |
| Serologic studies                    | No growth                             |
| Neoplastic                           | Negative (Histoplasma capsulatum, Blastomyces, Coccidioides, Cryptococcus neoformans, Treponema pallidum, Bartonella henselae, Borrelia burgdorferi, Toxocara, Brucella, Mycobacterium tuberculosis, Tropheryma whipplei, Varicella, Epstein-Barr virus, cytomegalovirus, human T-lymphotropic virus, human T-lymphotropic virus I and II and human immunodeficiency virus) |
| PET                                   | Normal                                 |
| Peripheral smear                      | Normal                                 |
| Bone marrow biopsy                    | Normal                                 |
| Brain biopsy                          | Atypical inflammatory demyelinating disease with well-demarcated areas of inflammation (reactive astrocytes, lymphocytes, macrophages, and activated microglia) with proportional loss of axons and myelin in a perivascular distribution|
| Cerebrospinal fluid flow cytometry   | Normal                                 |

Abbreviations: ANA, antinuclear antibody; PET, positron emission tomography.
Note: Bold items indicate notable findings.

sequencing revealed a candidate gene for Behçet disease to be located between the coding regions for HLA B and tumor necrosis factor.8

Behçet disease can also be classified as an autoinflammatory disease with a degree of symptom overlap with another autoinflammatory disease, Familial Mediterranean fever. Indeed, one study of patients with Behçet disease revealed a higher than expected mutation rate in the gene associated with Familial Mediterranean fever, MEFV.9 The presence of neutrophils in the pathologic lesions of Behçet disease further supports the important role of the innate immune system in the development of this disease.

The most common symptoms of Behçet disease in adult and pediatric cases are oral aphthous ulceration (95%-100%) and uveitis (30%-75%).4 A broad spectrum of other manifestations have been described, including rashes, arthritis, arterial and venous vasculitis, and central nervous system lesions. When compared to adults, children are less likely to have genital ulcers and vascular lesions but are more likely to have arthralgia and central nervous system symptoms.10 In 1990, the International Study Group for Behçet Disease11 published criteria for the diagnosis of Behçet disease requiring the presence one mandatory criteria (recurrent oral aphthous ulcers) and at least 2 minor criteria, which are listed in Table 2.

The spectrum of central nervous system findings in neuro-Behçet disease can vary widely. Metreau-Vastel et al12 described a series of 12 children with neuro-Behçet disease in 2010. In this report, they describe focal neurologic deficits as the most common symptom, occurring in 4 of 12 patients. Recurrent meningoencephalitis and rhombencephalitis were the second most common findings, each occurring in 2 of 12 patients. Interestingly, one patient in that case series had psychiatric symptoms at disease onset. Nonspecific psychiatric symptoms have been described in other cases, including changes in affect, auditory and visual hallucinations, and suicidal behavior.13

No standardized treatment has been proposed for Behçet disease or neuro-Behçet disease as the presentation and involved organ systems vary widely. The European League Against Rheumatism (EULAR) published a set of guidelines, based on an analysis of published literature, for the treatment of Behçet disease organized by affected organ system.14
In these guidelines, cyclosporine A was described as a highly effective agent for the treatment of ocular disease. However, as later noted, cyclosporine A has been shown to potentiate neurologic symptoms in several cases of Behçet disease and so should not generally be utilized in patients having Behçet disease with preexisting central nervous system symptoms. Although, no randomized, controlled trial has been conducted for the treatment of neuro-Behçet disease, azathioprine, corticosteroids, and methotrexate have been used in published reports.

In addition, more recent reports have described the off-label use of antitumor necrosis factor agents (ie, infliximab, etanercept, and adalimumab) with promising results. Due to its use in the treatment of lupus-related neuropsychiatric symptoms and a relatively good side effect profile, we chose to utilize azathioprine as a steroid-sparing agent in our patient and were able to achieve an excellent outcome.

Acknowledgments
The authors wish to thank Nicholas J. Silvestros, OD, for providing the retinal angiography images and the Department of Pathology for the biopsy images.

Author Contributions
ZAV, RG, BWO, and AJW contributed equally to this work.

Declaration of Conflicting Interests
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

References
1. Zouboulis CC, Keitel W. A historical review of early descriptions of Adamantiades-Behçet’s disease. J Invest Dermatol. 2002; 119(1):201-205. doi:10.1046/j.1523-1747.2002.01798.x.
2. Behçet H, Matteson EL. On relapsing, aphthous ulcers of the mouth, eye and genitalia caused by a virus. 1937. Clin Exp Rheumatol. 2010;28(4 suppl 60):S2-S5.
3. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet’s disease. N Engl J Med. 1999;341(17):1284-1291. doi:10.1056/NEJM199910213411707.
4. Saylan T, Mat C, Fresko I, Melikoğlu M. Behçet’s disease in the Middle East. Clin Dermatol. 1999;17(2):209-223.
5. Baricordi OR, Sensi A, Pivetti-Pezzi P, et al. Behçet’s disease associated with HLA-B51 and DRw52 antigens in Italians. Hum Immunol. 1986;17(3):297-301.
6. Lee S, Bang D, Cho YH, Lee ES, Sohn S. Polymerase chain reaction reveals herpes simplex virus DNA in saliva of patients with Behçet’s disease. Arch Dermatol Res. 1996;288(4):179-183.
7. Emmi L, Brugnolo F, Salvati G, Marchione T. Immunopathological aspects of Behçet’s disease. Clin Exp Rheumatol. 1995;13(6):687-691.
8. Mizuki N, Ohno S, Sato T, et al. Microsatellite polymorphism between the tumor necrosis factor and HLA-B genes in Behçet’s disease. Hum Immunol. 1995;43(2):129-135.

Table 2. International Study Group for Behçet Disease Diagnostic Criteria.

| Mandatory criteria (required) | Minor criteria (at least 2 required) |
|-----------------------------|------------------------------------|
| • Recurrent oral aphthous ulcers (at least 3 occurrences in a 12-month period) | • Recurrent genital ulcers |
| • Eye lesions | • Skin lesions (ie, erythema nodosum) |
| • Positive pathergy test | |

Figure 2. Fluorescein retinal angiography OS. Arrows highlight extravasation of fluorescein dye.

Figure 3. Luxol fast blue/periodic acid Schiff 10×. Marked demyelination on the left of the line compared to the normal white matter on the right. On the left, the vessels appear darker. The inflammation extends from these vessels (arrow) and is somewhat clustered around these areas.

Table 2. International Study Group for Behçet Disease Diagnostic Criteria.
9. Atagunduz P, Ergun T, Direskeneli H. MEFV mutations are increased in Behçet’s disease (BD) and are associated with vascular involvement. *Clin Exp Rheumatol*. 2003;21(4 suppl 30):S35-37.

10. Öen K. Comparative epidemiology of the rheumatic diseases in children. *Curr Opin Rheumatol*. 2000;12(5):410-414.

11. Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease. *Lancet*. 1990;335(8697):1078-1080.

12. Metreau-Vastel J, Mikaeloff Y, Tardieu M, Koné-Paut I, Tran TA. Neurological involvement in paediatric Behçet’s disease. *Neuropediatrics*. 2010;41(5):228-234. doi:10.1055/s-0030-1269909.

13. Deniz O, Çayköyilü A, Vural G, et al. A case study of Neuro-psycho-Behçet’s Syndrome presenting with psychotic attack. *Clin Neurol Neurosurg*. 2009;111(10):877-879. doi:10.1016/j.clinneu.2009.07.009.

14. Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet disease. *Ann Rheum Dis*. 2008;67(12):1656-1662. doi:10.1136/ard.2007.080432.

15. Arida A, Fragiadaki K, Giavri E, Sifakis PP. Anti-TNF agents for Behçet’s disease: analysis of published data on 369 patients. *Semin Arthritis Rheum*. 2011;41(1):61-70. doi:10.1016/j.semarthrit.2010.09.002.